Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKRP) Asset Writedowns and Impairment (2016 - 2024)

Bruker's Asset Writedowns and Impairment history spans 12 years, with the latest figure at $32.7 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment rose 32800.0% year-over-year to $32.7 million; the TTM value through Dec 2024 reached $54.3 million, up 198.35%, while the annual FY2025 figure was $76.0 million, 26.25% up from the prior year.
  • Asset Writedowns and Impairment reached $32.7 million in Q4 2024 per BRKRP's latest filing, up from $20.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $32.7 million in Q4 2024 to a low of -$1.9 million in Q3 2022.
  • Average Asset Writedowns and Impairment over 3 years is $7.4 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 106.25% in 2023, then skyrocketed 32800.0% in 2024.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $1.6 million in 2022, then crashed by 106.25% to -$100000.0 in 2023, then surged by 32800.0% to $32.7 million in 2024.
  • Per Business Quant, the three most recent readings for BRKRP's Asset Writedowns and Impairment are $32.7 million (Q4 2024), $20.2 million (Q2 2024), and $1.4 million (Q1 2024).